1814 related articles for article (PubMed ID: 8500110)
1. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
[TBL] [Abstract][Full Text] [Related]
2. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
3. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
[TBL] [Abstract][Full Text] [Related]
6. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
7. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
8. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
9. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
Nakamura K; Tanaka Y; Shitara K; Hanai N
Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
[TBL] [Abstract][Full Text] [Related]
10. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
11. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
Scott AM; Liu Z; Murone C; Johns TG; MacGregor D; Smyth FE; Lee FT; Cebon J; Davis ID; Hopkins W; Mountain AJ; Rigopoulos A; Hanai N; Old LJ
Cancer Immun; 2005 Feb; 5():3. PubMed ID: 15723450
[TBL] [Abstract][Full Text] [Related]
12. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
[TBL] [Abstract][Full Text] [Related]
14. A new vector for the high level expression of chimeric antibodies in myeloma cells.
Shitara K; Nakamura K; Tokutake-Tanaka Y; Fukushima M; Hanai N
J Immunol Methods; 1994 Jan; 167(1-2):271-8. PubMed ID: 8308283
[TBL] [Abstract][Full Text] [Related]
15. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
Honsik CJ; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
[TBL] [Abstract][Full Text] [Related]
17. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
18. Construction and expression of chimeric antibodies by a simple replacement of heavy and light chain V genes into a single cassette vector.
Kanda H; Mori K; Koga H; Taniguchi K; Kobayashi H; Sakahara H; Konishi J; Endo K; Watanabe T
Hybridoma; 1994 Oct; 13(5):359-66. PubMed ID: 7860092
[TBL] [Abstract][Full Text] [Related]
19. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD
Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781
[TBL] [Abstract][Full Text] [Related]
20. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
